A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

Sharafi, Faezeh; Hasani, Sadegh Abaei; Alesaeidi, Samira; Kahrizi, Mohammad Saeed; Adili, Ali; Ghoreishizadeh, Shadi; Shomali, Navid; Tamjidifar, Rozita; Aslaminabad, Ramin; Akbari, Morteza

doi:10.1186/s12935-022-02682-z

Cited by 6 publications

(4 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the APCs in liver show immunosuppressive action [ 97 , 110 ]. Besides, prolonged exposure to antigens induced expression of immunosuppressive checkpoint molecules and T cell exhaustion in liver [ 111 – 113 ]. These immune tolerance processes may be suppressed by the bacteria and antigen clearance effect of antibiotics, which may play a synergistic role with immunotherapy in anti-tumor therapy.…”

Section: Manipulation Of the Gut Microbiota To Enhance Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Zhang,

Liu,

Xia

2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients’ response to immunotherapy. Several characteristics of the gut microbiome, such as community structures, taxonomic compositions, and molecular functions, have been identified as crucial biomarkers for predicting immunotherapy response and immune-related adverse events (irAEs). Unlike other -omics, the gut microbiome can serve as not only biomarkers but also potential targets for enhancing the efficacy of immunotherapy. Approaches for modulating the gut microbiome include probiotics/prebiotics supplementation, dietary interventions, fecal microbiota transplantation (FMT), and antibiotic administration. This review primarily focuses on elucidating the potential role of the gut microbiome in predicting the response to cancer immunotherapy and improving its efficacy. Notably, we explore reasons behind inconsistent findings observed in different studies, and highlight the underlying benefits of antibiotics in liver cancer immunotherapy.

show abstract

Section: Manipulation Of the Gut Microbiota To Enhance Immunotherapymentioning

confidence: 99%

“…In addition to monotherapy, immunotherapy can be combined with other immunotherapy drugs or other treatments to improve the antitumor response [ 111 ]. For example, the combination of atezolizumab and bevacizumab has been approved as a first-line systemic treatment for advanced liver cancer patients.…”

Section: Further Directionsmentioning

confidence: 99%

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Zhang,

Liu,

Xia

2023

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Further, most patients lost the chance of surgery because of vascular invasion or even metastasis. For these advanced HCC, systemic treatments including immune treatment are highly recommended ( Sharafi et al, 2022 ). Among various solid tumors, immune treatment is especially widely used in HCC.…”

Section: Introductionmentioning

confidence: 99%

A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: Integrated analysis of bulk and single-cell RNA sequencing

Zheng

Zhang

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Myeloid cells are physiologically related to innate immunity and inflammation. Tumor-associated myeloid cells gained increasing interest because of their critical roles in tumor progression and anticancer immune responses in human malignancies. However, the associations between tumor-associated myeloid cell-related genes and hepatocellular carcinoma have yet to be revealed. Here, through the integrating analysis of bulk and single-cell RNA (scRNA) sequencing of public HCC samples, we developed a gene signature to investigate the role of HCC-specific myeloid signature genes in HCC patients. We firstly defined 317 myeloid cell marker genes through analyzing scRNA data of HCC from the GEO dataset. After selecting the differentially expressed genes, eleven genes were also proved prognostic. Then we built a gene signature from the TCGA cohort and verified further with the ICGC dataset by applying the LASSO Cox method. An eight genes signature (FABP5, C15orf48, PABPC1, TUBA1B, AKR1C3, NQO1, AKR1B10, SPP1) was achieved finally. Patients in the high risk group correlated with higher tumor stages and poor survival than those in the low-risk group. The risk score was proved to be an independent risk factor for prognosis. The high risk group had higher infiltrations of dendritic cells, macrophages and Tregs. And the APC co-inhibition, T cell co-inhibition pathways were also activated. Besides, the risk score positively correlated with multidrug resistance proteins. In conclusion, our myeloid cell marker genes related signature can predict patients’ survival and may also indicate the levels of immune infiltration and drug resistance.

show abstract

“…Hepatocellular carcinoma is one the malignant tumor that affects the liver cells and has the highest rate of morbidity, and mortality in the world [1,2]. The hepatocellular has various characteristics that show its uniqueness among other cancer like fast progression, recurrence, and a highly malignant property with a high rate of metastasis [1,3]. Hepatocellular carcinoma is a complex type of disease with the comparison to the other type of cancer [4].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Cytotoxic Activity of Quercetin and Silymarin and Their Synergistic Effect on Hep G2 Cell Lines

Raut¹,

Deore²,

Shirode³

2023

Preprint

View full text Add to dashboard Cite

Purpose One of the biggest causes of mortality among people is cancer. Plants may contain potential bioactive substances that might be used to provide "new leads" in the fight against cancer and other disorders. The main objective of this present study was to evaluate the cytotoxic activities of Quercetin and Silymarin and their Synergistic effect on Hep G2. Method The cytotoxic activity of this individual drug and in combination was confirmed by the consideration of IC50 by MTT assay. Results The results show that IC50 of Quercetin 50 µg, Silymarin 40 µg, and combination 30 µg respectively. The combination of these drugs shows a significant increase in cytotoxic effect and anti-proliferative effect compared with individual drugs. Thus, the results indicate that this combination has anti -hyper carcinogenic effect.

show abstract

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

Cited by 6 publications

References 113 publications

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: Integrated analysis of bulk and single-cell RNA sequencing

In Vitro Cytotoxic Activity of Quercetin and Silymarin and Their Synergistic Effect on Hep G2 Cell Lines

Contact Info

Product

Resources

About